The Committee on Psychopharmacology is GAP's newest committee. The Committee was established at the request of the Executive Committee, and had its inaugural meeting in the fall of 1998. The Committee is comprised of members with a wide range of professional expertise; including psychopharmacology, psychoanalysis, academics, private industry, private practice and the federal government.
The goal of the Committee is to examine issues related to psychopharmacology from a broad-based eclectic perspective. The initial project is a comprehensive review of the role of omega-3-fatty acids in the treatment of depression. The publication strategy is to focus on journal articles and short reports. At present, there are no plans to develop a full-length manuscript. The committee intends to maintain a GAP perspective in addressing issues pertaining to the ever-expanding field of psychopharmacology.